Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitor

What Was Tested

This randomized controlled trial looks at Bradykinin.

The effects of dialyzer membrane material and concurrent angiotensin converting enzyme (ACE) inhibitor on plasma bradykinin levels during hemodialysis were investigated by administration of 3 successive hemodialyses using a PAN DX membrane dialyzer and another 3 using a polysulfone membrane dialyzer with the order of the 2 sequences randomized, for 6 patients receiving concurrent treatment with ACE inhibitor and 6 others receiving no ACE inhibitor.

Who Took Part

The abstract describes 6 patients taking part.

The age groups tagged for this paper are middle-aged adults.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The effects of dialyzer membrane material and concurrent angiotensin converting enzyme (ACE) inhibitor on plasma bradykinin levels during hemodialysis were investigated by administration of 3 successive hemodialyses using a PAN DX membrane dialyzer and another 3 using a polysulfone membrane dialyzer with the order of the 2 sequences randomized, for 6 patients receiving concurrent treatment with ACE inhibitor and 6 others receiving no ACE inhibitor.

Topics PubMed links to this paper include Anaphylaxis, Angiotensin-Converting Enzyme Inhibitors, Bradykinin, Membranes, Artificial, Polymers, Renal Dialysis and Renal Insufficiency.

What This Means in Plain Language

The paper is a randomized study of Bradykinin in 6 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Clinical nephrology), a journal based in Germany.

More context: the Bradykinin compound page, all human trials.